The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate (5) cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic (10) castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.本発明は、雄の被験体において黄体形成ホルモン(LH)の低減によって、またはLHレベルとは無関係に、テストステロンレベルを低減させる方法、ならびに前立腺がん、進行性前立腺がん、去勢抵抗性前立腺がん(CRPC)、転移性去勢抵抗性前立腺がん(mCRPC)を処置する、抑制する、発生率を低減させる、重症度を低減させる、または阻害する方法、ならびに前立腺がん、進行性前立腺がん、去勢抵抗性前立腺がん(CRPC)および転移性去勢抵抗性前立腺がん(mCRPC)の待機療法、ならびに前立腺がん、進行性前立腺がん、去勢抵抗性前立腺がん(CRPC)および転移性去勢抵抗性前立腺がん(mCRPC)を患っている被験体において高いもしくは増加するPSAレベルを低減させ、かつ/またはSHBGレベルを増加させる方法に関する。
